Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
dc.contributor.author | Cunniffe, N | en_US |
dc.contributor.author | Vuong, KA | en_US |
dc.contributor.author | Ainslie, D | en_US |
dc.contributor.author | Baker, D | en_US |
dc.contributor.author | Beveridge, J | en_US |
dc.contributor.author | Bickley, S | en_US |
dc.contributor.author | Camilleri, P | en_US |
dc.contributor.author | Craner, M | en_US |
dc.contributor.author | Fitzgerald, D | en_US |
dc.contributor.author | de la Fuente, AG | en_US |
dc.contributor.author | Giovannoni, G | en_US |
dc.contributor.author | Gray, E | en_US |
dc.contributor.author | Hazlehurst, L | en_US |
dc.contributor.author | Kapoor, R | en_US |
dc.contributor.author | Kaur, R | en_US |
dc.contributor.author | Kozlowski, D | en_US |
dc.contributor.author | Lumicisi, B | en_US |
dc.contributor.author | Mahad, D | en_US |
dc.contributor.author | Neumann, B | en_US |
dc.contributor.author | Palmer, A | en_US |
dc.contributor.author | Peruzzotti-Jametti, L | en_US |
dc.contributor.author | Pluchino, S | en_US |
dc.contributor.author | Robertson, J | en_US |
dc.contributor.author | Rothaul, A | en_US |
dc.contributor.author | Shellard, L | en_US |
dc.contributor.author | Smith, KJ | en_US |
dc.contributor.author | Wilkins, A | en_US |
dc.contributor.author | Williams, A | en_US |
dc.contributor.author | Coles, A | en_US |
dc.date.accessioned | 2020-11-18T11:02:42Z | |
dc.date.available | 2020-10-13 | en_US |
dc.date.issued | 2020-11-12 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/68421 | |
dc.description.abstract | OBJECTIVE: To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis (MS). METHODS: We long-listed licensed drugs with evidence of human safety, blood-brain barrier penetrance and demonstrable efficacy in at least one animal model, or mechanistic target, agreed by a panel of experts and people with MS to be relevant to the pathogenesis of progression. We systematically reviewed the preclinical and clinical literature for each compound, condensed this into a database of summary documents and short-listed drugs by scoring each one of them. Drugs were evaluated for immediate use in a clinical trial, and our selection was scrutinised by a final independent expert review. RESULTS: From a short list of 55 treatments, we recommended four treatments for immediate testing in progressive MS: R-α-lipoic acid, metformin, the combination treatment of R-α-lipoic acid and metformin, and niacin. We also prioritised clemastine, lamotrigine, oxcarbazepine, nimodipine and flunarizine. CONCLUSIONS: We report a standardised approach for the identification of candidate drugs for repurposing in the treatment of progressive MS. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | J Neurol Neurosurg Psychiatry | en_US |
dc.title | Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. | en_US |
dc.type | Article | |
dc.rights.holder | © Author(s) (or their employer(s)) 2020.Published by BMJ. | |
dc.identifier.doi | 10.1136/jnnp-2020-324286 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33184094 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
dcterms.dateAccepted | 2020-10-13 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |